Michael B. Dwinell, PhD

Professor; Founding Director, Center for Immunology; Director, Bobbie Nick Voss Laboratory for Colon Cancer Research; Hanis-Stepka-Rettig Endowed Chair in Cancer Research

Locations

Microbiology & Immunology
TBRC C3860

Contact Information

General Interests

Cancer Metastasis, Tumor Microenvironment, Mucosal Inflammation

Education

PhD, GI Pathophysiology, University of Wisconsin, Madison, 1996

Learn more about the Dwinell Lab

Biography

Dr. Dwinell, Hanis-Stepka-Rettig Endowed Chair in Cancer Research, is the Founding Director of the Center for Immunology following its inception in 2018. He has completed an MCW executive leadership training program at the Sheldon Lubar School of Business at the University of Wisconsin-Milwaukee as well as the Leadership for Social Inclusion & Equity Workshop developed by the National Coalition Building Institute. He has served on numerous NIH review panels and is currently chair of the Tumor Microenvironment study section.

Dr. Dwinell’s laboratory uses innovative strategies to reprogram the immune microenvironment to overcome immune suppression and evasion in pancreatic cancer. Specifically, his grant supported research examines chemokines as pivotal immune messengers regulating the tumor immune microenvironment. Dr. Dwinell oversees the immunology curriculum in Infectious Agents and Host Immunity and is past Director for Gastrointestinal & Nutritional Pathophysiology in the MCW medical school. He is course director of Mucosal Immunity and teaches in the Foundations in Biomedical Sciences and several other graduate school courses. He has frequently been named an Outstanding Medical Student and Outstanding Graduate Student Teacher and was recognized with the MCW Outstanding Mentor award in 2018.

Research Interests

My research interests currently focus on mechanisms tumor progression including remodeling the immune microenvironment. I use a variety of cellular, biochemical, and preclinical approaches to study the mechanisms immune-cancer cell communication essential for cancer progression.

Synthesis of fluorinated triphenylphosphonium analogs that improve cancer cell selectivity and in vivo detection.

(Keyes RF, McAllister D, Dwinell MB, Smith BC.) STAR Protoc. 2023 Aug 07;4(3):102437 PMID: 37552599 PMCID: PMC10424135 SCOPUS ID: 2-s2.0-85175638505 08/08/2023
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.

(Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A.) Bone Marrow Transplant. 2023 Aug;58(8):953-955 PMID: 37149674 PMCID: PMC10555486 SCOPUS ID: 2-s2.0-85158126520 05/07/2023
Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28.

(Zhou AL, Jensen DR, Peterson FC, Thomas MA, Schlimgen RR, Dwinell MB, Smith BC, Volkman BF.) SLAS Discov. 2023 Jun;28(4):163-169 PMID: 36841432 PMCID: PMC10339762 SCOPUS ID: 2-s2.0-85149845436 02/26/2023
A modified ELISA assay differentiates CCL20 locked dimers from wild-type monomers.

(Wu X, Clarke WR, Koplinski CA, Peterson FC, Dwinell MB, Wei G, Chao E, Huynh M, Yamada D, Volkman BF, Hwang ST.) J Immunol Methods. 2023 Apr;515:113453 PMID: 36863695 SCOPUS ID: 2-s2.0-85150034077 03/03/2023
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma.

(D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S.) Bone Marrow Transplant. 2023 Mar;58(3):334-336 PMID: 36460820 SCOPUS ID: 2-s2.0-85143207078 12/03/2022
DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence.

(Elmansi AM, Eisa NH, Periyasamy-Thandavan S, Kondrikova G, Kondrikov D, Calkins MM, Aguilar-Pérez A, Chen J, Johnson M, Shi XM, Reitman C, McGee-Lawrence ME, Crawford KS, Dwinell MB, Volkman BF, Blumer JB, Luttrell LM, McCorvy JD, Hill WD.) ACS Pharmacol Transl Sci. 2023 Jan 13;6(1):22-39 PMID: 36659961 PMCID: PMC9844133 01/21/2023
Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches.

(Vonderhaar EP, Dwinell MB, Craig BT.) Front Immunol. 2023;14:1202169 PMID: 37426669 PMCID: PMC10325564 SCOPUS ID: 2-s2.0-85164152167 07/10/2023
DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence

(Elmansi AM, Eisa NH, Periyasamy-Thandavan S, Kondrikova G, Kondrikov D, Calkins MM, Aguilar-Pérez A, Chen J, Johnson M, Shi XM, Reitman C, McGee-Lawrence ME, Crawford KS, Dwinell MB, Volkman BF, Blumer JB, Luttrell LM, McCorvy JD, Hill WD.) ACS Pharmacology and Translational Science. 13 January 2023;6(1):22-39 SCOPUS ID: 2-s2.0-85143982229 01/13/2023
Physiology of chemokines in the cancer microenvironment.

(Drouillard D, Craig BT, Dwinell MB.) Am J Physiol Cell Physiol. 2023 Jan 01;324(1):C167-C182 PMID: 36317799 PMCID: PMC9829481 SCOPUS ID: 2-s2.0-85145954846 11/02/2022
Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin.

(AbuEid M, Keyes RF, McAllister D, Peterson F, Kadamberi IP, Sprague DJ, Chaluvally-Raghavan P, Smith BC, Dwinell MB.) iScience. 2022 Dec 22;25(12):105670 PMID: 36567718 PMCID: PMC9768319 12/27/2022
Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin

(AbuEid M, Keyes RF, McAllister D, Peterson F, Kadamberi IP, Sprague DJ, Chaluvally-Raghavan P, Smith BC, Dwinell MB.) iScience. 22 December 2022;25(12) SCOPUS ID: 2-s2.0-85143723525 12/22/2022
The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.

(Jørgensen AS, Brandum EP, Mikkelsen JM, Orfin KA, Boilesen DR, Egerod KL, Moussouras NA, Vilhardt F, Kalinski P, Basse P, Chen YH, Yang Z, Dwinell MB, Volkman BF, Veldkamp CT, Holst PJ, Lahl K, Goth CK, Rosenkilde MM, Hjortø GM.) Cell Mol Life Sci. 2021 Nov;78(21-22):6963-6978 PMID: 34586443 PMCID: PMC8558179 SCOPUS ID: 2-s2.0-85116031161 09/30/2021